EC Number   |
Inhibitors |
Structure |
|---|
    2.7.8.13 | 3'-O-(2R)-1-(methylamino-1-oxopropan-2-yl)-tunicamycin V |
MurNAc analogue of tunicamycin. The inhibitor does not show toxicity against HepG2 cells up to 100 microM, and is a non-toxic selective MraY inhibitor |
   |
| 2.7.8.13 | 3'-O-(2R)-1-(methylamino-1-oxopropan-2-yl)-tunicamycin V |
MurNAc analogue of tunicamycin. The inhibitordoes not show toxicity against HepG2 cells up to 100 microM, and is a non-toxic selective MraY inhibitor.The inhibitor retains weak antibacterial activity against Staphylococcus aureus, the MIC value is reduced compared to tunicamycin |
|
| 2.7.8.13 | 5'-O-(5-amino-5-deoxy-beta-D-ribofuranosyl)-3'-deoxy-3',3'-difluorouridine |
low inhibition (29% at 11.4 mM), analogue of a liposidomycin (potent and selective inhibitor) assembled from lactol and gem-difluoromethylenated nucleoside with 1,2-trans-beta-furanoside linkage |
|
| 2.7.8.13 | A-94964 |
- |
|
| 2.7.8.13 | Amphomycin |
- |
|
| 2.7.8.13 | caprazamycin B |
- |
|
| 2.7.8.13 | CPZEN-45 |
CPZEN-45 strongly inhibits incorporation of radiolabeled glycerol into growing cultures and shows antibacterial activity against caprazamycin-resistant strains, including a strain overexpressing translocase-I MraY, involved in the biosynthesis of peptidoglycan, the target of the caprazamycins. Very poor inhibition by vancomycin |
|
| 2.7.8.13 | Cs+ |
- |
|
| 2.7.8.13 | dodecylamine |
a competitive inhibitor of MraY |
|
| 2.7.8.13 | EDTA |
complete inhibition at 2 mM |
|
